
Sign up to save your podcasts
Or


Biotech stocks eye-popping run has investors nervous of a bubble. Healthcare Fool's Michael Douglass and Todd Campbell weigh in with their take on biotech valuation.
By The Motley FoolBiotech stocks eye-popping run has investors nervous of a bubble. Healthcare Fool's Michael Douglass and Todd Campbell weigh in with their take on biotech valuation.